Multiple Myeloma, Multiple Sclerosis, Breast Cancer Drugs Are Among Those Going Off Patent in 2020

AIS Health asked various industry experts about what specialty drugs are expected to see patent expiration — and potentially generic or biosimilar competition — in 2020. Here’s what Martin Burruano, R.Ph., vice president, pharmacy services at Independent Health; April M. Kunze, Pharm.D., senior director, clinical formulary development and trend management strategy at Prime Therapeutics LLC; and Mesfin Tegenu, R.Ph., president of PerformRx, LLC, told us:

Eligard (leuprolide acetate): prostate cancer,

Forteo (teriparatide): osteoporosis,

Juxtapid (lomitapide): familial hypercholesterolemia,

Korlym (mifepristone): endocrine gland diseases,

Lucentis (ranibizumab): macular degeneration,

Pomalyst (pomalidomide): multiple myeloma,

Sprycel (dasatinib): acute lymphoblastic leukemia and chronic myeloid leukemia,

Tecfidera (dimethyl fumarate): multiple sclerosis (MS),

Thalomid (thalidomide): multiple myeloma and leprosy,

Truvada (emtricitabine/tenofovir disoproxil fumarate): HIV-1 infection and HIV pre-exposure prophylaxis (PrEP),

Tykerb (lapatinib): breast cancer, and

Tysabri (natalizumab): MS.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_article_Anthem_Launches_Voluntary.jpg
September 9

Anthem Launches Voluntary Oncology Dose Reduction Program

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Home_Infusion_Policies.jpg
September 9

Legislation Seeks to Change Medicare Home Infusion Policies

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Specialty_Trend.jpg
September 9

Specialty Trend Increase Slows; Biosimilars Are Having Impact

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today